Finance

Lists
3349:TYO
Cosmos Pharmaceutical Corp
Â¥6,436.00
-3.12%
(-207.00) 1D
Sep 18, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 3349...
Open
Â¥6,544
High
Â¥6,620
Low
Â¥6,436
Mkt. cap
514.89B
Avg. vol.
405.56K
Volume
710.30K
Dividend
1.27%
Quarterly dividend
Â¥21
Ex-dividend date
Nov 27, 2026
P/E ratio
15.92
52-wk high
Â¥8,980
52-wk low
Â¥5,615
EPS
Â¥404
Shares outstanding
19.80M
No. of employees
6K
Open
Â¥6,544
High
Â¥6,620
Low
Â¥6,436
Mkt. cap
514.89B
Avg. vol.
405.56K
Volume
710.30K
Dividend
1.27%
Quarterly dividend
Â¥21
Ex-dividend date
Nov 27, 2026
P/E ratio
15.92
52-wk high
Â¥8,980
52-wk low
Â¥5,615
EPS
Â¥404
Shares outstanding
19.80M
No. of employees
6K
About Cosmos Pharmaceutical Corp
CEO-
Employees5.98K
FoundedDec 1983
Headquarters-
SectorDrug
Websitecosmospc.co.jp
Last report
Jul 13, 2026
Fiscal period
Q4 2026
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
289.20B / 284.97B
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Aug 2025
Nov 2025
Feb 2026
May 2026
Revenue
272.39B
264.78B
273.20B
289.20B
Cost of goods sold
215.22B
209.07B
216.15B
229.46B
Cost of revenue
215.22B
209.07B
216.15B
229.46B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
45.64B
46.57B
45.83B
26.43B
Operating expense
45.64B
46.57B
45.83B
49.08B
Total operating expenses
260.86B
255.64B
261.97B
278.54B
Operating income
11.54B
9.14B
11.23B
10.66B
Other non operating income
627.00M
801.00M
667.00M
695.00M
EBT including unusual items
12.09B
9.58B
11.96B
10.60B
EBT excluding unusual items
12.08B
9.85B
11.81B
11.12B
Income tax expense
3.92B
3.10B
3.86B
1.30B
Effective tax rate
32.40%
32.35%
32.26%
12.26%
Other operating expenses
-
-
-
-
Net income
8.17B
6.48B
8.10B
9.30B
Net profit margin
3.00%
2.45%
2.96%
3.21%
Earnings per share
-
-
-
-
Interest and investment income
27.00M
19.00M
16.00M
12.00M
Interest expense
-110.00M
-107.00M
-107.00M
-257.00M
Net interest expenses
-83.00M
-88.00M
-91.00M
-245.00M
Depreciation and amortization charges
-
-
-
22.64B
EBITDA
17.09B
15.00B
16.79B
16.81B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps